Status: Recruiting
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.
Participants needed: 56
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, DavisUpdated: Feb 9, 2026Locations: 1
Eligibility criteria
Participants must have histologically confirmed non-small cell lung cancer that... [+4]
Tumor with known sensitizing alteration in ALK, EGFR, HER2, MET exon 14, NTRK, R... [+3]